» Articles » PMID: 35664985

An Appraisal of Laboratory Models of Androgenetic Alopecia: A Systematic Review

Overview
Journal Skin Health Dis
Specialty Dermatology
Date 2022 Jun 6
PMID 35664985
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Androgenetic alopecia (AGA) is the most common form of non-scarring alopecia in humans. Several studies have used different laboratory models to study the pathogenesis and interventions for AGA. These study models have proved beneficial and have led to the approval of two drugs. However, the need to build on existing knowledge remains by examining the relevance of study models to the disease.

Objective: We sought to appraise laboratory or pre-clinical models of AGA.

Method: We searched through databases (PubMed, ScienceDirect, Web of Science, World CAT, Scopus and Google Scholar) for articles on AGA-related studies from 1942 to March 2019 with a focus on study models.

Results: The search rendered 101 studies after screening and deduplication. Several studies (70) used in vitro models, mostly consisting of two-dimensional monolayer cells for experiments involving the characterization of androgen and 5-alpha reductase (5AR) and inhibition thereof, the effects of dihydrotestosterone (DHT) and biomarker(s) of AGA. Twenty-seven studies used in vivo models of mice and monkeys to investigate DHT synthesis, the expression and inhibition of 5AR and hair growth. Only four studies used AGA-related or healthy excisional/punch biopsy explants as ex vivo models to study the action of 5AR inhibitors and AGA-associated genes. No study used three-dimensional [3-D] organoids or organotypic human skin culture models.

Conclusion: We recommend clinically relevant laboratory models like human or patient-derived 3-D organoids or organotypic skin in AGA-related studies. These models are closer to human scalp tissue and minimize the use of laboratory animals and could ultimately facilitate novel therapeutics.

Citing Articles

Improvement of androgenic alopecia by extracellular vesicles secreted from hyaluronic acid-stimulated induced mesenchymal stem cells.

Oh H, Jung M, Jeong S, Kim J, Han S, Kim H Stem Cell Res Ther. 2024; 15(1):287.

PMID: 39256806 PMC: 11389250. DOI: 10.1186/s13287-024-03906-x.


Androgenetic alopecia: An update.

Ntshingila S, Oputu O, Arowolo A, Khumalo N JAAD Int. 2023; 13:150-158.

PMID: 37823040 PMC: 10562178. DOI: 10.1016/j.jdin.2023.07.005.


Bioengineered skin organoids: from development to applications.

Hong Z, Zhu S, Li H, Luo J, Yang Y, An Y Mil Med Res. 2023; 10(1):40.

PMID: 37605220 PMC: 10463602. DOI: 10.1186/s40779-023-00475-7.


Biomaterials for Treatment of Baldness.

Sahu P, Ramteke H Cureus. 2022; 14(11):e31187.

PMID: 36505112 PMC: 9727726. DOI: 10.7759/cureus.31187.

References
1.
Bruchovsky N, Wilson J . The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem. 1968; 243(8):2012-21. View

2.
Dey-Rao R, Sinha A . A genomic approach to susceptibility and pathogenesis leads to identifying potential novel therapeutic targets in androgenetic alopecia. Genomics. 2017; 109(3-4):165-176. DOI: 10.1016/j.ygeno.2017.02.005. View

3.
Kwack M, Ahn J, Kim M, Kim J, Sung Y . Preventable effect of L-threonate, an ascorbate metabolite, on androgen-driven balding via repression of dihydrotestosterone-induced dickkopf-1 expression in human hair dermal papilla cells. BMB Rep. 2010; 43(10):688-92. DOI: 10.5483/BMBRep.2010.43.10.688. View

4.
Wang Z, Feng Y, Ma L, Li X, Ding W, Chen X . Hair growth promoting effect of white wax and policosanol from white wax on the mouse model of testosterone-induced hair loss. Biomed Pharmacother. 2017; 89:438-446. DOI: 10.1016/j.biopha.2017.02.036. View

5.
Thornton M, Laing I, Hamada K, Messenger A, Randall V . Differences in testosterone metabolism by beard and scalp hair follicle dermal papilla cells. Clin Endocrinol (Oxf). 1993; 39(6):633-9. DOI: 10.1111/j.1365-2265.1993.tb02420.x. View